Trials / Completed
CompletedNCT01111890
Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects are dosed twice daily at 9AM and 9PM for 12 weeks. The primary efficacy variable is the mean change in Intraocular Pressure (IOP) from baseline to 12 weeks. Secondary efficacy variable: % IOP ≤ 18 millimeters mercury (mmHg). Exploratory endpoint: Ocular discomfort scale after first dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azarga (brinzolamide 1% / timolol 0.5%) | Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks |
| DRUG | Cosopt (dorzolamide 2% / timolol 0.5%) | Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-04-28
- Last updated
- 2015-07-29
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01111890. Inclusion in this directory is not an endorsement.